Stevanato Group Investor Relations

Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value added solutions to clients.

Latest News

Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026

View Press Release

Liraglutide Combination Products Incorporating Stevanato Group's Alina® Pen Injector Received Marketing Authorizations in Multiple European Countries

View Press Release

Stevanato Group to Report Second Quarter 2026 Financial Results on August 4, 2026

View Press Release

Stevanato Group Introduces Deora™, a Pen Injector for Subcutaneous Delivery in Diabetes and Weight Management

View Press Release

Latest Financial Results

Q2 2026

Quarter Ended Jun 30, 2026

Earnings Release
PDF HTML
Audio
Earnings Webcast
Prepared Comments
PDF

We respect your privacy. We do not sell, rent, or loan any information to any third party.
Any information you give us is held with the utmost care and security, and will be used
only in ways indicated in our Privacy Policy.

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2025

Report Links

IR and Media Contacts

Company

Stevanato Group S.p.A.
Via Molinella 17
Piombino Dese, Padua 35017
Italy

Investor Relations

Lisa Miles
Chief Communications and Investor Relations Officer
lisa.miles@stevanatogroup.com

Giacomo Guiducci
Strategic Marketing and Investor Relations
giacomo.guiducci@stevanatogroup.com

Media

Caterina Tripepi
Media Relations
caterina.tripepi@stevanatogroup.com